2 terminated, 2 withdrawn, 1 active not recruiting, 1 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 2, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow BioAge Labs, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF - Diabetic Macular Edema (DME) | Phase 2 | Recruiting | BioAge Labs, Inc. | 180 | 2026-08-21 | 2026-09-10 |
| A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors Oral BGE-102, Oral Placebo Matching BGE-102 - Obesity and Cardiovascular Risk | Phase 2 | Active not recruiting | BioAge Labs, Inc. | 160 | 2026-06-11 | 2026-09-10 |
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide - Obesity | Phase 2 | Terminated | BioAge Labs, Inc. | 204 | 2024-06-27 | 2025-03-13 |
| Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers Azelaprag - Healthy Volunteer Study | Phase 1 | Completed | BioAge Labs, Inc. | 16 | 2023-11-17 | 2024-02-23 |
| Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery BGE-117, 4mg, Ferrous Sulfate, Matching Placebo - Acute Posthemorrhagic Anemia | Phase 2 | Withdrawn | BioAge Labs, Inc. | 2022-04-01 | 2022-05-05 | |
| Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging BGE-117, Placebo - Anemia | Phase 2 | Withdrawn | BioAge Labs, Inc. | 2021-03-22 | 2022-05-05 | |
| Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure BGE-175, Placebo - Covid19 | Phase 2 | Terminated | BioAge Labs, Inc. | 194 | 2021-03-18 | 2023-07-03 |
Anemia (2) · Obesity (2) · COVID-19 (1) · Diabetic Retinopathy (1) · Respiratory Insufficiency (1)
Tirzepatide (1) · asapiprant (1) · ferrous sulfate (1) · salicylhydroxamic acid (1)
United States (4) · Australia (2) · Argentina (1) · Brazil (1) · New Zealand (1) · Puerto Rico (1)
Patrick Martin, MD (1) · Richard G Wilkerson, MD (1)